{"id":57568,"date":"2024-07-24T12:03:46","date_gmt":"2024-07-24T12:03:46","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/07\/24\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/"},"modified":"2024-07-24T12:03:46","modified_gmt":"2024-07-24T12:03:46","slug":"sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/","title":{"rendered":"SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study"},"content":{"rendered":"<div>\n<p><b>SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US, <span class=\"xn-location\">Europe<\/span> and <span class=\"xn-location\">Israel<\/span><\/b><\/p>\n<p>TEL AVIV,\u00a0Israel, <span class=\"xn-chron\">July 24, 2024<\/span> \/PRNewswire\/ &#8212;\u00a0<a href=\"https:\/\/sonivie.com\/\" target=\"_blank\" rel=\"nofollow noopener\">SoniVie<\/a>, which has developed a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS<sup>&#x2122;<\/sup>) to treat a variety of hypertensive disorders, presented on <span class=\"xn-chron\">May 15<\/span><sup>th<\/sup>, 2024 at the EuroPCR conference (<span class=\"xn-location\">Paris, France<\/span>)\u00a0the results of its renal denervation REDUCED-1 pilot study, along with a case presentation of the first-in-human treatment with the TIVUS<sup>&#x2122;<\/sup>\u00a0Radial Access Catheter.<\/p>\n<p>Dr. <span class=\"xn-person\">James Zidar<\/span> (<span class=\"xn-org\">University of North Carolina<\/span>, NC) presented the 3-month primary efficacy data from the REDUCED-1 Pilot study (N=40 patients, 25 in US and 15 in <span class=\"xn-location\">Israel<\/span>): an average -12.0 mmHg reduction in daytime ambulatory systolic blood pressure (ASBP) comparing baseline to 3-month was obtained, with 78.4% of patients being responders (\u22655mm reduction in daytime ASBP). The responder ASBP 3-month average reduction was -16.2mmHg. No device related adverse events were reported in the 1-month primary safety endpoint analysis, and efficacy data are sustained at 6-month follow-up.<\/p>\n<p>&#8220;This is the first no-touch RDN device that is not required to be in contact with the renal artery vessel wall, which is unique as the other RDN technologies to date require contact&#8221; commented the EuroPCR panel of discussants and renal denervation experts.<\/p>\n<p>Professor <span class=\"xn-person\">Michael Jonas<\/span> (Kaplan, <span class=\"xn-location\">Israel<\/span>) introduced the 4Fr Rapid Exchange Radial Access TIVUS<sup>&#x2122;<\/sup>\u00a0Catheter as the newest evolution of RDN technologies and presented the first-in-human clinical case performed.<\/p>\n<p>More recently, on <span class=\"xn-chron\">July 17<\/span><sup>th<\/sup>, 2024, the FDA approved the THRIVE study, an international, multicentre, randomized, double blind, sham-controlled study, designed to demonstrate the adjunctive effectiveness and safety of the TIVUS<sup>&#x2122;<\/sup>\u00a0System in hypertensive subjects while subjects are maintained off-antihypertensive medications for a 4-week wash-out period before RDN\/Sham procedure and 2 months after procedure. \u00a0At 2 months after procedure, subjects with uncontrolled hypertension are put back on antihypertensive medication according to a medication escalation protocol. Unblinding will be performed at 6 months. Uncontrolled sham subjects can crossover to TIVUS<sup>&#x2122;<\/sup>\u00a0at 6-months.\u00a0 The THRIVE Study is led by a Global Steering Committee comprised of Dr. <span class=\"xn-person\">Ajay Kirtane<\/span> (<span class=\"xn-org\">Columbia University<\/span> Medical Center, <span class=\"xn-location\">New York City<\/span>, NY), Dr. <span class=\"xn-person\">Michel Azizi<\/span> (George Pompidou Hospital, <span class=\"xn-location\">Paris, France<\/span>) and Dr. <span class=\"xn-person\">Felix Mahfoud<\/span> (University of <span class=\"xn-location\">Basel<\/span>, <span class=\"xn-location\">Basel, Switzerland<\/span>).<\/p>\n<p>&#8220;The SoniVie clinical operations teams throughout US, <span class=\"xn-location\">Europe<\/span> and <span class=\"xn-location\">Israel<\/span> are now supporting sites, physicians and patients participating in the global pivotal THRIVE Study, anticipating enrollment of the first patient in the fourth quarter of 2024&#8243;, says <span class=\"xn-person\">Tomaso Zambelli<\/span>, Chief Executive Officer, SoniVie.<\/p>\n<p>Renal Denervation with TIVUS&#x2122; is a minimally invasive procedure that uses a high-frequency non-focused ultrasound energy catheter which does not anchor to the vessel wall during treatment to ablate nerves in the surrounding tissue located along the renal arteries, thereby reducing sympathetic activity which lowers blood pressure.<\/p>\n<p><b>About SoniVie<\/b><\/p>\n<p>SoniVie is a medical device company developing the TIVUS&#x2122;\u00a0System, the only platform denervation technology with active development programs in three therapeutic areas: renal artery denervation for resistant hypertension, pulmonary artery denervation for pulmonary hypertension, and total lung denervation for chronic obstructive pulmonary disease with chronic bronchitis. These diseases affect millions of patients around the world.<\/p>\n<p>The company&#8217;s offices are located in Rehovot, <span class=\"xn-location\">Israel<\/span> and in <span class=\"xn-location\">Minneapolis, MN<\/span>, USA<\/p>\n<p>Contact:<br \/><span class=\"xn-person\">Tomaso Zambelli<\/span><br \/>CEO, Sonivie<br \/><a href=\"mailto:tomaso@sonivie.com\" target=\"_blank\" rel=\"nofollow noopener\"><b>tomaso@sonivie.com<\/b><\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US, Europe and Israel TEL AVIV,\u00a0Israel, July 24, 2024 \/PRNewswire\/ &#8212;\u00a0SoniVie, which has developed a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS&#x2122;) to treat a variety of hypertensive disorders, presented on May 15th, 2024 at the [&#8230;]\n","protected":false},"author":1,"featured_media":79226,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-57568","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study\" \/>\n<meta property=\"og:description\" content=\"SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US, Europe and Israel TEL A\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-24T12:03:46+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study\",\"datePublished\":\"2024-07-24T12:03:46+00:00\",\"dateModified\":\"2024-07-24T12:03:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/\"},\"wordCount\":568,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/\",\"name\":\"SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-07-24T12:03:46+00:00\",\"dateModified\":\"2024-07-24T12:03:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/","og_locale":"en_US","og_type":"article","og_title":"SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study","og_description":"SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US, Europe and Israel TEL A","og_url":"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-07-24T12:03:46+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study","datePublished":"2024-07-24T12:03:46+00:00","dateModified":"2024-07-24T12:03:46+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/"},"wordCount":568,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/","url":"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/","name":"SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-07-24T12:03:46+00:00","dateModified":"2024-07-24T12:03:46+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/sonivie-announces-advancements-in-its-renal-denervation-program-reduced-1-pilot-study-results-radial-access-first-in-human-results-and-fda-pivotal-ide-approval-of-the-thrive-global-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/57568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=57568"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/57568\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/79226"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=57568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=57568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=57568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}